Meiragtx Holdings (MGTX)
NASDAQ:MGTX
Want to see MGTX full AI Analyst Report?
MGTX Stock Chart & Stats
$10.12
-$0.03(-0.47%)
At close: 4:00 PM EST
$10.12
-$0.03(-0.47%)
Day’s Range― - ―
52-Week Range$6.07 - $11.85
Previous CloseN/A
Volume124.17K
Average Volume (3M)720.70K
Market Cap
$889.05M
Enterprise Value$1.00B
Total Cash (Recent Filing)$71.54M
Total Debt (Recent Filing)$87.53M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 06, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding92,609,510
10 Day Avg. Volume781,063
30 Day Avg. Volume720,696
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue12.57
Enterprise Value/Gross Profit13.71
Enterprise Value/Ebitda-10.47
Forecast
1Y Price Target
$24.00Price Target Upside137.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$49.29M
Bulls Say, Bears Say
Bulls Say
High Gross Margin & Improving Cash FlowA ~94% gross margin combined with TTM positive operating cash flow (~$8M) indicates strong unit economics and improving cash generation. Over the medium term this supports reinvestment into late-stage programs and reduces reliance on emergency financing if operating cash conversion is sustained.
Strategic Partnerships & Extended RunwayLarge strategic deals (Hologen JV, pharma commercialization arrangements) plus a $93M equity raise materially extend funding visibility into H2 2028. These structural funding and partnership arrangements lower execution risk for clinical development, manufacturing scale-up, and potential commercialization.
Clinical & Regulatory MomentumBreakthrough Therapy designation and sustained Phase 1 durability position AAV2-hAQP1 for an accelerated regulatory path and potential BLA timing. This reduces development time and regulatory risk versus typical timelines, improving prospects for earlier revenue generation and payer engagement if confirmatory data succeed.
Bears Say
Negative Equity PositionA negative shareholders' equity (~-$58M) constrains financial flexibility and can complicate access to capital or favorable borrowing terms. Over months this condition increases reliance on external funding, potential asset sales, or dilution to support commercialization and late-stage trials.
Large Ongoing Net LossesSizable TTM net losses (~$121M) versus ~$80M revenue show the business has not scaled to cover operating costs. Persistent deficits amplify funding needs and dilution risk, and require sustained revenue growth or margin expansion to reach breakeven within a multi-quarter horizon.
Free Cash Flow Weakness & VolatilityDespite positive operating cash flow, free cash flow is slightly negative (~-$2M TTM) and has deteriorated year-over-year, signaling ongoing investment and working-capital variability. This persistent FCF shortfall implies continued financing needs and limits near-term self-funding of launches and scale-up activities.
Meiragtx Holdings News
MGTX FAQ
What was Meiragtx Holdings’s price range in the past 12 months?
Meiragtx Holdings lowest stock price was $6.07 and its highest was $11.85 in the past 12 months.
What is Meiragtx Holdings’s market cap?
Meiragtx Holdings’s market cap is $889.05M.
When is Meiragtx Holdings’s upcoming earnings report date?
Meiragtx Holdings’s upcoming earnings report date is Aug 06, 2026 which is in 54 days.
How were Meiragtx Holdings’s earnings last quarter?
Meiragtx Holdings released its earnings results on May 14, 2026. The company reported -$0.57 earnings per share for the quarter, beating the consensus estimate of -$0.606 by $0.036.
Is Meiragtx Holdings overvalued?
According to Wall Street analysts Meiragtx Holdings’s price is currently Undervalued.
Does Meiragtx Holdings pay dividends?
Meiragtx Holdings does not currently pay dividends.
What is Meiragtx Holdings’s EPS estimate?
Meiragtx Holdings’s EPS estimate is -0.31.
How many shares outstanding does Meiragtx Holdings have?
Meiragtx Holdings has 92,609,510 shares outstanding.
What happened to Meiragtx Holdings’s price movement after its last earnings report?
Meiragtx Holdings reported an EPS of -$0.57 in its last earnings report, beating expectations of -$0.606. Following the earnings report the stock price went down -0.201%.
Which hedge fund is a major shareholder of Meiragtx Holdings?
Currently, no hedge funds are holding shares in MGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Meiragtx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (137.15% Upside)
$24.00 (137.15% Upside)
Blogger Sentiment
Bullish
MGTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 144.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.14%
12-Months-Change
Fundamentals
Return on Equity
474.91%
Trailing 12-Months
Asset Growth
9.21%
Trailing 12-Months
Company Description
Meiragtx Holdings
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
MGTX Stock 12 Month Forecast
Average Price Target
$24.00
▲(137.15% Upside)
Technical Analysis
Ownership Overview
15.65% Insiders
1.86% Mutual Funds
57.31% Other Institutional Investors
21.73% Public Companies and
Individual Investors